CSN Login
Members Online: 1

You are here

Metastatic Breast Cancer Survey - Trodelvy

Date: 
Monday, June 21, 2021 - 12:30pm
Your announcement.: 

My name is MJ DeCoteau and I am the executive director of Rethink Breast Cancer (www.rethinkbreastcancer.com) – a Canadian patient group dedicated to building community for young women dealing with breast cancer and providing support and resources to help them live the best quality of life.

The Canadian government will soon be reviewing the use of Trodelvy (sacituzumab govitecan) to treat unresectable locally advanced or metastatic triple-negative breast cancer who have received at least two prior therapies, including at least one prior therapy for locally advanced or metastatic disease. Rethink Breast Cancer will be making a submission to ensure that patient voices are represented and considered during the review process.

Does this survey apply to you?

We are looking for patients with metastatic triple-negative breast cancer and patients who have been treated with Trodelvy to talk about their treatment experience.

YOU DO NOT NEED TO LIVE IN CANADA TO PARTICIPATE.

If you are interested in talking about your experiences, we would like to ask you to complete this survey: https://www.surveymonkey.com/r/trodelvy

If you would like to speak with us directly about your cancer or treatment experience, you can contact me at survey@rethinkbreastcancer.com.

MJ DeCoteau
Founder + Executive Director
Rethink Breast Cancer

 

Check the appropriate category for your announcement: 
Research study, clinical trial, focus group,etc (Requires IRB review and certification. See here for guidelines.)
Contact - Email: 
survey@rethinkbreastcancer.com
Contact - First name: 
MJ
Contact - Last name: 
DeCouteau
Contact - Telephone number: 
416 220 0700
Subscribe to Comments for "Metastatic Breast Cancer Survey - Trodelvy "